论文部分内容阅读
在云南南部，用青蒿琥酯６００ｍｇ、伯喹１８０ｍｇ和氯喹１５００ｍｇ、伯喹１８０ｍｇ，均以８ｄ分服，分别治疗３３例和３５例间日疟患者，平均退热时间各为（１８．７±３．９）ｈ和（２５．４±１２．０）ｈ，平均原虫转阴时间各为（２８．７±６．１）ｈ和（４２．９±６．２）ｈ。观察９个月内的复发率分别为３３．３％和２２．９％。结果表明，青蒿琥酯与伯喹联用治疗间日疟，其退热时间和原虫转阴时间均显著快于氯喹与伯喹联用组（Ｐ均＜０．０１），而复发率则无明显差别（Ｐ＞０．０５），且副反应更轻，患者易于接受。因此，是治疗间日疟的安全有效方案。
In the southern part of Yunnan Province, artemisuetine 600mg, primaquine 180mg, chloroquine 1500mg and primaquine 180mg were given for 8d, and the average duration of fever was (18.7 ± 3.9 h, and (25.4 ± 12.0) h, respectively. The average protozoal anastomosis time was (28.7 ± 6.1) h and (42.9 ± 6.2) h respectively. The recurrence rates within 9 months were 33.3% and 22.9% respectively. The results showed that the combination of artesunate and primaquine in the treatment of P. vivax was significantly faster than that of chloroquine and primaquine (P <0.01), while the relapse rate was No significant difference (P> 0.05), and less side effects, patients are easy to accept. Therefore, it is a safe and effective treatment for vivax malaria.